This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

BAM-15

Investigational

Mitochondrial protonophore | tissue-targeted uncoupler | DNP-class without plasma-membrane effect

Aliases (4)

BAM15 · tissue-targeted mitochondrial uncoupler · selective mitochondrial protonophore · BAM 15

TYPICAL DOSE

Unknown in humans

No human dose validated

ROUTE

Oral (research-chem capsule/powder)

Oral capsule or powder

CYCLE

8-12 weeks (community-typical)

Community-typical 8-12 weeks (no safety basis)

STORAGE

Room temp; sealed, dry, dark

Sealed, dark, dry

Overview

What is BAM-15?

BAM-15 is an investigational small-molecule mitochondrial protonophore (aromatic furazano-bis-imidazole, ~401 Da) designed to be a 'tissue-targeted' mitochondrial uncoupler — selective for the inner mitochondrial membrane without depolarizing the plasma membrane. Conceptually, it is the safer reimagining of DNP (2,4-dinitrophenol), the 1930s-era weight-loss drug that killed dozens of users by causing lethal hyperthermia. BAM-15 has shown fat-mass reduction, NAFLD reversal, and insulin sensitization in rodents without observable hyperthermia at therapeutic doses. As of May 2026 it remains preclinical-only — no published Phase 1, no FDA approval, no IND on public record, and no entry on the WADA Prohibited List. Sold strictly as a research chemical by gray-market vendors.

Key Benefits

Rodent fat loss without caloric restriction; rodent NAFLD reversal; rodent insulin sensitization; mechanism is class-defining (selective mitochondrial uncoupling) and represents the most credible 'safer DNP' chemotype to date. None of these benefits has been demonstrated in humans.

Mechanism of Action

Protonophore — a small lipophilic molecule that shuttles protons across the inner mitochondrial membrane, collapsing the H+ gradient (Δψm) that ATP synthase normally uses to make ATP. Substrate oxidation continues at the electron transport chain, but the chemical energy is dissipated as heat rather than captured as ATP. Net effect: caloric inefficiency — the body burns more substrate (fat, glucose) per unit of ATP produced. Unlike DNP, BAM-15 spares the plasma-membrane potential, which is the structural basis for its wider therapeutic index in rodents (Childress 2018). The same mechanism that drives fat loss is also the failure mode: too much uncoupling, too fast, dumps energy as heat the body cannot dissipate — the lethal hyperthermia mechanism that killed DNP users.

Research Indications

Most Effective

What a protonophore does — the thermodynamics

In a normally-coupled mitochondrion, the electron transport chain (complexes I-IV) pumps protons (H+) from the matrix across the inner mi…

Effective

The DNP precedent — why this class has a body count

2,4-dinitrophenol (DNP) is the parent protonophore. Marketed as a weight-loss agent in the 1930s; killed at least 60+ documented users in…

Investigational

What makes BAM-15 different — the "tissue-targeted" claim

BAM-15 (Kenwood et al. 2014, Mol Metab) was designed by the Kenwood / Hoehn group at the University of Virginia to uncouple mitochondria …

Investigational

Rodent efficacy — Alexopoulos 2020 and follow-ups

Alexopoulos et al. 2020 (Nature Communications) is the headline mouse efficacy paper. In diet-induced-obese C57BL/6J mice, oral BAM-15 (~…

Investigational

What we genuinely don't know about BAM-15 in humans

- Human PK. No published Phase 1. Half-life, oral bioavailability, plasma protein binding, hepatic clearance pathway, CNS penetration — a…

Investigational

Plain English

BAM-15 is a chemical that punches molecular holes in your mitochondria so they leak energy as heat instead of using it to make ATP. The b…

Peptide Interactions

None recommended.

Synergistic

No stack synergy is currently mechanistically justified for BAM-15 in humans. The compound itself has no human safety data; building stacks on top of it comp…

DNP

Avoid

additive uncoupling, additive lethal hyperthermia risk. Hard avoid.

Cardarine (GW-501516)

Avoid

both push fat oxidation hard; theoretical additive hepatic and metabolic load; Cardarine has its own carcinogenicity concerns. Hard avoid.

SLU-PP-332

Avoid

both target the mitochondrial substrate-oxidation axis from different angles; no human safety data on either; functional opposition (SLU-PP-332 builds mitoch…

MOTS-c

Avoid

same logic as SLU-PP-332; mitochondrial-pathway-pushing compounds should not be stacked with an uncoupler.

Semaglutide / tirzepatide / retatrutide

Avoid

these are the FDA-approved, evidence-based answer to the same goal. No basis to add an unvalidated uncoupler to a working GLP-1 protocol.

Stimulants

Avoid

(caffeine high-dose, modafinil, ephedrine, clenbuterol, yohimbine) — stimulants raise metabolic rate and core temp on their own; layering on an uncoupler rep…

Thyroid hormone (T3/T4)

Avoid

additive thermogenic and cardiac load; do not combine.

Pre-workout supplements with high stimulant content

Avoid

same logic; mechanistic risk amplification.

Quality Indicators

Research-Chem Sourcing Only

BAM-15 is not available through any FDA-approved channel, compounding pharmacy, or clinical trial supply chain. All sourcing is gray-market research-chem with high lot-to-lot purity variance.

COA / HPLC Verification Mandatory

Demand a Certificate of Analysis with HPLC purity ≥98% and ideally mass-spec confirmation. Independent third-party testing (Janoshik or similar) on a representative lot is appropriate due diligence for any uncoupler given the thermodynamic mechanism.

No Human PK Anchor

Community doses (typically 25-100 mg/day oral) are extrapolated from rodent surface-area scaling without any human Phase 1 PK study. Sub-therapeutic and supra-therapeutic doses are both possible.

✗

Mechanism Class Has Killed

DNP, the parent protonophore class, has caused dozens of confirmed deaths from hyperthermia and is associated with cataracts, agranulocytosis, and hepatotoxicity. BAM-15 is designed to avoid plasma-membrane effects but has no human safety data to confirm the rodent therapeutic-index advantage translates.

✗

No Phase 1 Published as of 2026

As of May 2026 there is no published human Phase 1 study, no IND on file publicly, and no registered trial for BAM-15 in any indication. The molecule is preclinical-only.

What to Expect

Week 1-2
Adaptation period. Most users report habituation to the warmth signal but a persistent low-grade thermogenic effect. Some report mild fatigue or reduced wor…
Week 2-6
Subjective fat loss in users running a caloric deficit; modest in users at maintenance. Mechanism predicts the body burns more substrate per unit of work, s…

Side Effects & Safety 8

Side Effects

1Increased perceived warmth / sweating — the primary subjective effect; consistent with mechanism
2Mild elevation in resting heart rate (typically 5-15 bpm)
3Mild fatigue or reduced workout output in some users — consistent with reduced ATP yield per substrate
4Modest fat loss at community doses
5Insomnia with evening dosing
6Mild nausea with high doses or empty-stomach dosing
7Headache
8Transient elevations in ALT / AST (reported in some users with bloodwork; magnitude variable)

When to Stop

Hyperthermia (the central mechanism-class risk). The DNP fatality mechanism. BAM-15 is designed to have a wider therapeutic index, but the wider-index claim is mouse-validated only. Hot environments, exertion, dehydration, stimulant co-use, thyroid co-use are the multiplicative risk factors. Heatstroke can be fatal within hours. This is the single biggest unknown risk.
Cardiac arrhythmia. Cardiac muscle is mitochondria-dense and oxidative. Uncoupling could theoretically destabilize cardiac rhythm under exertion or stress. No human cardiac safety data.
Hepatotoxicity. Liver is the major site of BAM-15 exposure (oral, hepatic first-pass) and substrate oxidation. ALT/AST monitoring in any cycle is mandatory. Mouse data does not show liver toxicity at therapeutic doses, but human translation is unverified.
Cataracts. A historical DNP-class side effect. Mechanism unclear; possibly mitochondrial uncoupling in lens epithelium. No BAM-15 cataract reports as of May 2026, but exposure base is tiny.
Agranulocytosis / hematologic toxicity. Historical DNP risk. No BAM-15 reports yet.
Long-term oncology. Mitochondrial uncoupling has complex effects on ROS, AMPK, and mTOR signaling — all of which interact with tumor biology. No chronic carcinogenicity data.
Reproductive / fertility tox. No data.
First 7 days: Daily AM oral temperature, daily resting HR (first thing in the morning). Discontinue if resting AM temp >37.8°C or resting HR persistently >15 bpm above baseline.
First 28 days: Continue daily monitoring; mid-cycle ALT/AST/CMP at day 14.
Hot weather: Hard avoid. Do not run a cycle during summer outdoor training, sauna use, or heated rooms.
Fight camp / intense training: Hard avoid.
Stimulants / caffeine: Eliminate or reduce caffeine to background levels during cycle. The user is already low-caffeine baseline; do not introduce a higher caffeine load mid-cycle.
Any pre-existing cardiac condition (arrhythmia, structural heart disease, heart failure)
Hypertension uncontrolled
Hyperthyroidism or thyroid medication use
Liver disease or elevated baseline ALT/AST
Pregnancy / lactation (zero data)
Pediatric use (zero data)
Concurrent stimulant use (caffeine high doses, modafinil, ephedrine, clenbuterol, recreational stimulants)
Concurrent thyroid hormone
Fight camp, weight-cut phase, or elite training under heat stress
Hot environments / summer outdoor training
Tested athletic competition (mechanism plausibly under S4.4 catch-all)